APOE and pTau217/pTau231 Blood Biomarker Assay Testing

The contract requires the performance of high-sensitivity blood assays to measure APOE and pTau217/pTau231 biomarkers using de-identified human samples, with the goal of supporting Alzheimer’s disease research by distinguishing between amyloid-positive and amyloid-negative individuals. The work involves precise laboratory analysis to generate reliable biological data that advances the understanding of early biomarker patterns associated with Alzheimer’s pathology. All samples must be handled in accordance with strict de-identification protocols to ensure participant privacy and compliance with ethical and regulatory standards. The contract is designated as a subcontract under NAICS code 541380, reflecting its classification within the scientific research and development services sector. It is managed by the Department of Veterans Affairs through its Rpo East (36C24E) office, with performance required to take place in Minneapolis, Minnesota, at zip code 55417. The solicitation was posted on April 29, 2026, and responses must be submitted no later than May 11, 2026, at 2:00 PM Eastern Time. There is no set-aside classification specified, and the contract does not include a designated point of contact within the provided information.